Petros Pharmaceuticals, Inc. (PTPI)
USD 0.25
(-7.78%)
USD 0.25
(-7.78%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -5.06 Million USD | -1710.61% |
| 2022 | 314.19 Thousand USD | 101.34% |
| 2021 | -23.44 Million USD | -135.26% |
| 2020 | -9.96 Million USD | -185.92% |
| 2019 | 11.59 Million USD | -73.88% |
| 2018 | 44.39 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 174.1 Thousand USD | 105.68% |
| 2024 Q1 | -3.06 Million USD | 39.4% |
| 2023 Q1 | 1.02 Million USD | 225.74% |
| 2023 FY | -5.06 Million USD | -1710.61% |
| 2023 Q3 | -9.28 Million USD | -696.79% |
| 2023 Q2 | 1.55 Million USD | 51.96% |
| 2023 Q4 | -5.06 Million USD | 45.48% |
| 2022 Q3 | -1.21 Million USD | 58.47% |
| 2022 Q2 | -2.93 Million USD | 58.67% |
| 2022 FY | 314.19 Thousand USD | 101.34% |
| 2022 Q1 | -7.09 Million USD | 69.72% |
| 2022 Q4 | 314.19 Thousand USD | 125.78% |
| 2021 Q1 | -9.5 Million USD | 4.61% |
| 2021 FY | -23.44 Million USD | -135.26% |
| 2021 Q4 | -23.44 Million USD | -293.55% |
| 2021 Q3 | -5.95 Million USD | 21.68% |
| 2021 Q2 | -7.6 Million USD | 19.98% |
| 2020 Q4 | -9.96 Million USD | -141.04% |
| 2020 FY | -9.96 Million USD | -185.92% |
| 2020 Q3 | 24.27 Million USD | 16.03% |
| 2020 Q2 | 20.92 Million USD | 41.83% |
| 2020 Q1 | 14.75 Million USD | 20.56% |
| 2019 Q4 | 12.23 Million USD | 0.0% |
| 2019 FY | 11.59 Million USD | -73.88% |
| 2019 Q1 | 2.79 Million USD | 0.0% |
| 2018 FY | 44.39 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 105.372% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 106.752% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 101.162% |
| Cosmos Health Inc. | 8.59 Million USD | 158.905% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 38.389% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 101.103% |
| Cronos Group Inc. | -663.32 Million USD | 99.237% |
| Incannex Healthcare Limited | -5.48 Million USD | 7.741% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 65.273% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 104.151% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | -74.41% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 67.634% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 67.634% |
| SCYNEXIS, Inc. | -19.35 Million USD | 73.848% |
| Safety Shot Inc | -2.28 Million USD | -121.522% |
| Theratechnologies Inc. | 24.87 Million USD | 120.347% |
| Alpha Teknova, Inc. | 1.97 Million USD | 356.352% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | 2666.001% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 101.169% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | -100.809% |
| Dynavax Technologies Corporation | 106.63 Million USD | 104.746% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 100.812% |
| Radius Health, Inc. | 359.28 Million USD | 101.408% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 46.336% |
| Alvotech | 1.06 Billion USD | 100.475% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 96.132% |
| SIGA Technologies, Inc. | -148.68 Million USD | 96.597% |
| Shineco, Inc. | 29.29 Million USD | 117.277% |
| Silver Spike Investment Corp. | -32.61 Million USD | 84.483% |
| Journey Medical Corporation | -9.7 Million USD | 47.879% |
| Embecta Corp. | 1.31 Billion USD | 100.386% |
| Harrow Health, Inc. | 116.41 Million USD | 104.347% |
| Procaps Group, S.A. | 242.93 Million USD | 102.083% |
| Biofrontera Inc. | 4.05 Million USD | 224.763% |
| DURECT Corporation | -7.65 Million USD | 33.886% |
| PainReform Ltd. | -7.95 Million USD | 36.347% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 84.907% |
| OptiNose, Inc. | 58.06 Million USD | 108.715% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 2.423% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 133.707% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | 4835.571% |
| ProPhase Labs, Inc. | 19.23 Million USD | 126.314% |
| Phibro Animal Health Corporation | 454.84 Million USD | 101.113% |
| Procaps Group S.A. | 242.93 Million USD | 102.083% |
| TherapeuticsMD, Inc. | 3.67 Million USD | 237.585% |
| Viatris Inc. | 17.13 Billion USD | 100.03% |
| Rockwell Medical, Inc. | 4.45 Million USD | 213.563% |
| Aytu BioPharma, Inc. | -4.87 Million USD | -3.76% |
| Tilray Brands, Inc. | 158.97 Million USD | 103.183% |
| PetIQ, Inc. | 351.93 Million USD | 101.438% |
| Talphera, Inc. | -5.72 Million USD | 11.547% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 102.854% |
| Alimera Sciences, Inc. | 55.3 Million USD | 109.149% |
| Assertio Holdings, Inc. | -32.52 Million USD | 84.443% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | -239.915% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | 220.0% |
| Hempacco Co., Inc. | 13.61 Million USD | 137.169% |
| Alvotech | 1.06 Billion USD | 100.475% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 94.767% |
| Kamada Ltd. | -46.43 Million USD | 89.101% |
| Currenc Group, Inc. | -16.57 Million USD | 69.466% |
| Indivior PLC | -33.95 Million USD | 85.095% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | 2042.014% |
| Flora Growth Corp. | -713 Thousand USD | -609.731% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 38.389% |
| Evolus, Inc. | 63.7 Million USD | 107.943% |
| HUTCHMED (China) Limited | -197.45 Million USD | 97.437% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 101.056% |
| Akanda Corp. | 3.9 Million USD | 229.59% |